Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
ARZERRA (ofatumumab) - Fatal Infusion Reaction Reported in a Patient with Chronic Lymphocytic Leukemia - For Health Professionals
- Starting date:
- August 6, 2014
- Posting date:
- August 6, 2014
- Type of communication:
- Dear Healthcare Professional Letter
- Source of recall:
- Health Canada
- Important Safety Information
- Healthcare Professionals
- Identification number:
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
Health Canada Endorsed Important Safety Information on ARZERRA (ofatumumab)
August 6, 2014
Dear Health Care Professional
Subject: ARZERRA™ (ofatumumab) – Fatal infusion reaction reported in a patient with Chronic Lymphocytic Leukemia (CLL) who received intravenous ofatumumab
GlaxoSmithKline Inc. (GSK), in consultation with Health Canada, would like to inform you of important new safety information regarding a fatal infusion-related reaction following the use of ARZERRA™ (ofatumumab).
ARZERRA™ is an anti-CD20 antibody that is authorized in Canada under a Notice of Compliance with conditions, for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
- A post-marketing case of fatal infusion reaction has been reported in a patient with CLL with no known history of cardiac disease.
- The current ARZERRATM Product Monograph is being updated to include the appropriate warnings and precautions to reflect the potential for fatal infusion reactions.
Health Care Professionals are reminded that serious infusion reactions may still occur with administration of ofatumumab despite premedication. If a severe infusion reaction is suspected, stop the infusion immediately and provide symptomatic treatment.
- Ofatumumab should be administered under the supervision of a physician experienced in the use of cancer therapy and in an environment where facilities to adequately monitor and treat infusion reactions are available. - Appropriate premedications should always be administered as prescribed in the product label.
Health care professionals should inform their patients regarding the risk of fatal infusion reactions associated with the use of ARZERRA™ (ofatumumab).
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious hypersensitivity or infusion reactions or other serious or unexpected adverse reactions in patients receiving ARZERRA™ should be reported to GlaxoSmithKline Inc. or Health Canada.
7333 Mississauga Road
To correct your mailing address or fax number, contact GlaxoSmithKline Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
- Calling toll-free at 1-866-234-2345; or
- Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
If you have any questions about this new information, please contact GlaxoSmithKline Medical Information Department at 1-800-387-7374.
original signed by
Dr. Sally Taylor
Country Medical Director, Canada
™ARZERRA is used under license by GlaxoSmithKline Inc.
For more informationThe update to the product monograph was not as a result of a Health Canada safety review. Therefore a Summary Safety Review is not available.
- Date modified: